We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fiat Chrysler (FCAU) Proposes $40B Merger Deal to Renault
Read MoreHide Full Article
Fiat Chrysler Automobiles N.V. proposed to collaborate with Renault SA (RNLSY - Free Report) of France to establish the third biggest automaker in the world, per Associated Press. The $40-billion proposed company will aggressively enter the electric and autonomous vehicles industry. With anticipated annual vehicle production of 8.7 million, the merged entity is likely to reshape the global auto industry.
The deal is likely to be beneficial for the companies. This would lead to annual savings of $5.6 billion in forms of sharing of research, purchase of costs and other activities. Importantly, the merger is likely to be a good fit as Renault boasts strong presence in Europe and has edge developing electric vehicles while Fiat Chrysler has robust presence in the United States and SUV markets. However, these companies are comparatively weak in China, the largest auto market in the world.
Recently, the auto industry tends to opt for consolidation. In fact, the pressure and reality to invest heavily in the development of electric cars, self-driving vehicles and in-car connectivity resulted in a growing number of consolidations in the global auto industry. In addition to this, regulators in China and Europe are pushing automakers to produce electric vehicles to comply with the stricter climate change regulations.
However, there are several hurdles before this mega merger. Problems may arise from the leadership position in the merged entity. Moreover, the cultural and geographical synchronization can create problems.
Shares of Fiat Chrysler have underperformed the industry it belongs to in the past three months. Over this time frame, shares of the company have fallen 13% compared with the industry’s decline of 7.2%.
While Renault currently carries a Zacks Rank #3 (Hold), Fiat Chrysler has a Zacks Rank #4 (Sell).
Ford has an expected long-term growth rate of 7.3%. Over the past three months, shares of the company have gained 11.9%.
Fox Factory has an expected long-term growth rate of 16.4%. Over the past three months, shares of the company have gained 5.3%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Fiat Chrysler (FCAU) Proposes $40B Merger Deal to Renault
Fiat Chrysler Automobiles N.V. proposed to collaborate with Renault SA (RNLSY - Free Report) of France to establish the third biggest automaker in the world, per Associated Press. The $40-billion proposed company will aggressively enter the electric and autonomous vehicles industry. With anticipated annual vehicle production of 8.7 million, the merged entity is likely to reshape the global auto industry.
The deal is likely to be beneficial for the companies. This would lead to annual savings of $5.6 billion in forms of sharing of research, purchase of costs and other activities. Importantly, the merger is likely to be a good fit as Renault boasts strong presence in Europe and has edge developing electric vehicles while Fiat Chrysler has robust presence in the United States and SUV markets. However, these companies are comparatively weak in China, the largest auto market in the world.
Recently, the auto industry tends to opt for consolidation. In fact, the pressure and reality to invest heavily in the development of electric cars, self-driving vehicles and in-car connectivity resulted in a growing number of consolidations in the global auto industry. In addition to this, regulators in China and Europe are pushing automakers to produce electric vehicles to comply with the stricter climate change regulations.
However, there are several hurdles before this mega merger. Problems may arise from the leadership position in the merged entity. Moreover, the cultural and geographical synchronization can create problems.
Shares of Fiat Chrysler have underperformed the industry it belongs to in the past three months. Over this time frame, shares of the company have fallen 13% compared with the industry’s decline of 7.2%.
While Renault currently carries a Zacks Rank #3 (Hold), Fiat Chrysler has a Zacks Rank #4 (Sell).
A couple of better-ranked stocks in the auto space are Ford Motor Company (F - Free Report) and Fox Factory Holding Corp. (FOXF - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ford has an expected long-term growth rate of 7.3%. Over the past three months, shares of the company have gained 11.9%.
Fox Factory has an expected long-term growth rate of 16.4%. Over the past three months, shares of the company have gained 5.3%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>